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Background: Dupuytren’s contracture (DC) is a progressive fibroproliferative disorder characterized by development
of nodules and collagen cords within the palmar fascia of the hand. Collagenase clostridium histolyticum (CCH) is
currently approved in adults with DC for the nonsurgical treatment of a single palpable cord during a 30-day
treatment cycle. This open-label pilot study was designed to examine the safety, efficacy, and multiple-dose
pharmacokinetics of injecting two cords (affected joints) with multiple doses of CCH concurrently into the same
hand in subjects with DC and multiple contractures.
Methods: Twelve subjects with DC were enrolled, each with ≥3 contractures caused by palpable cords. Efficacy
assessments were taken 30 days after treatment and adverse events (AEs) were recorded throughout. In the first
treatment period, all subjects were injected with a single dose of CCH (0.58 mg) into a single cord. The same
subjects entered a second treatment period 30 days later, where two different cords (affected joints) were injected
concurrently on the same hand. A finger extension procedure was performed 24 hours after each administration of
CCH to disrupt the enzymatically weakened cord.
Results: For metacarpophalangeal (MP) joints, mean contracture reduction per joint treated was 29.0 ± 20.7 degrees
following single injection vs 30.3 ± 10.9 degrees per treated joint following multiple injections. For proximal
interphalangeal (PIP) joints, mean reduction in contracture was 30.7 ± 21.1 and 22.1 ± 4.9 degrees per treated joint,
respectively, for the two periods. All patients (100%) were either “quite satisfied” or “very satisfied” following either
treatment cycle. The most common treatment-related AEs were edema peripheral, contusion, and pain in the
treated extremity; the differences in severity for local effects of the injections were minimal between treatment
periods. No serious treatment-related AEs or systemic complications were reported.
Conclusion: These results provide preliminary evidence that two cords (affected joints) can be treated concurrently
with CCH with similar efficacy and safety as cords treated individually in a sequential fashion. Multiple concurrent
injections would eliminate the 30-day wait between single treatments and allow for rapid and effective treatment
of patients with multiple affected joints, a significant advantage for both patient and physician.
Trial registration: Australian New Zealand Clinical Trials Registry #ACTRN12610001045000.
Keywords: Dupuytren’s disease, contracture, palpable cord, nonsurgical treatment, collagenase clostridium
histolyticum (CCH), multiple injections, metacarpophalangeal joint, proximal interphalangeal joint* Correspondence: sgcoleman@optusnet.com.au
1Brisbane Hand and Upper Limb Clinic, Level 9, 259 Wickham Terrace,
Brisbane Queensland. 4000, Australia
Full list of author information is available at the end of the article
© 2012 Coleman et al.; licensee BioMed Centr
Commons Attribution License ( http://creativec
reproduction in any medium, provided the origal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Coleman et al. BMC Musculoskeletal Disorders 2012, 13:61 Page 2 of 8
http://www.biomedcentral.com/1471-2474/13/61Background
Dupuytren’s contracture (DC) is a chronic, progressive
fibroproliferative disorder that affects the hand. In the
early stages of DC, abnormal myofibroblasts contribute
to the formation of nodules, and as the disease prog-
resses collagen deposits in the palm lead to the develop-
ment of pathologic cords. Subsequent contraction of
these cords results in flexion deformity and ultimately in
contracture of the metacarpophalangeal (MP) and
proximal interphalangeal (PIP) joints [1,2]. MP and PIP
joints of the ring and small finger are most commonly
affected [3,4]. Bilateral disease occurs frequently, and is
considered to be a risk factor for development of an
aggressive course of disease and a higher incidence of
disease recurrence following surgical correction [4,5].
There is currently no cure for DC, and surgical correc-
tion of contractures has typically been the only accepted
treatment option once the disease has progressed to the
point of limiting the patient’s daily activities. Generally,
surgical intervention is indicated once the contracture has
increased to >30 degrees for MP joints and >15 degrees
for PIP joints with identification of a palpable cord [1,6].
Several different surgical procedures are available for
correction of DC, including simple fasciotomy, needle
aponeurotomy, limited, partial, or regional fasciectomy,
total or radical fasciectomy, and dermofasciectomy [1,7,8].
The different surgical procedures can address multiple
affected joints on the same hand and generally have good
results, but there can be complications from surgery, such
as nerve or artery injury [9,10]. Particularly, the length of
recovery time needed to return to daily activities following
surgery is of concern to many patients [6].
Collagenase clostridium histolyticum (CCH; XiaflexW,
XiapexW; Auxilium Pharmaceuticals/Pfizer Inc.) is a clin-
ically effective, minimally invasive nonsurgical treatment
of DC with a palpable cord that may have a better
morbidity profile than surgical interventions [11,12].
CCH is comprised of a fixed-ratio mixture of two
purified enzymes, a clostridial type I collagenase (AUX-I)
and a clostridial type II collagenase (AUX-II), that work
synergistically to enzymatically disrupt the collagen
structure within DC cords [11]. Previously published
phase III clinical studies have demonstrated CCH to be a
safe and effective treatment option for patients with DC
[13,14]. In both studies, more patients treated with CCH
had a reduction in contracture to 0–5 degrees compared
to placebo (64.0% vs 6.8% and 44.4% vs 4.8%, respec-
tively; p< 0.001 for each study). The vast majority of
AEs were local, mild to moderate in severity, confined to
the treated extremity, and generally resolved without
intervention prior to the next injection [13,14]. CCH is
indicated for injection of only one cord at a time, and
any additional palpable cords with contractures of MP or
PIP joints should be injected with CCH sequentially withapproximately 4 weeks between injections. The current
study was conducted to determine if concurrent
administration of two 0.58-mg injections of CCH into
two palpable cords on the same hand in subjects with
DC would result in comparable safety and efficacy
results as to a single injection into one cord.Methods
Study population
This open-label study was conducted at a single center
in Australia. Subjects were eligible for study inclusion if
they were in general good health and between the ages
of 18 and 70. Subjects were required to have a diagnosis
of DC with at least 3 fixed-flexion contractures, caused
by palpable cords, that were ≥20 in PIP and/or MP
joints in fingers (not the thumbs). The disease had to be
severe enough that the subjects could not simultaneously
place the affected finger(s) and palm flat against a table
top. Exclusion criteria included previous treatment of the
selected joints within 90 days of first dose of study drug;
chronic muscular, neurologic, or neuromuscular disor-
ders affecting the hands; known allergy to collagenase;
collagenase treatment or treatment with any investiga-
tional drug within 30 days of first dose of study drug;
anticoagulant within 7 days of first dose of study drug
(with the exception of low-dose aspirin or NSAIDs);
breastfeeding or pregnancy; and known history of stroke,
bleeding disorder, or other medical condition that in the
opinion of the investigator would compromise the
subjects’ safety or the study objectives. All participants
provided written informed consent and were free to
discontinue at any time. The study protocol was approval
by a local ethics committee (Queensland Institute of
Medical Research, HREC #P1315), and research was
carried out in compliance with the Declaration of
Helsinki as currently amended.Study design
An overview of the study design can be found in Figure 1.
In the first treatment period, all subjects were given a
single injection of CCH (0.58 mg; volume of 0.25 mL for
MP joints and 0.20 mL for PIP joints) into a single cord.
A finger extension procedure was conducted within 24
hours post-dosing, as described previously [14]. Local
anesthesia could be used during the finger extension
procedure in the first treatment period, but was not
required. Subjects were bandaged for the first few days
following the finger extension procedure and then were
fitted for a splint to be worn each night for up to
4 months.
The same subjects entered a second treatment period
30 days later, where two different affected joints on the
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Figure 1 Study design. CCH= collagenase clostridium histolyticum; PK = pharmacokinetic.
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of blood samples for pharmacokinetic analysis began on
day 31, on the same visit as the injection for treatment
period 2. The finger extension procedure without local
anesthesia (to avoid any possible confounding effects
on the pharmacokinetic evaluation) was performed at
approximately 24 hours.Efficacy and safety assessments
Efficacy assessments, including joint contracture (mea-
sured by finger goniometry) and range of motion of
the affected joint were made before dosing (day 1 for
treatment period 1; day 31 for treatment period 2), and
at follow-up visits during each treatment period (days 7
and 30 for treatment period 1; days 37 and 60 for
treatment period 2). Subject satisfaction with treatment
was reported at the end of each treatment period (day 30
and day 60) using a five-level Likert response scale
(1. Very Satisfied, 2. Quite Satisfied, 3. Neither Satisfied
nor Dissatisfied, 4. Quite Dissatisfied, 5. Very Dissatisfied).
Safety was monitored by recording AEs (relationship to
drug assessed as probable, possible or not related), vital
sign measurements, laboratory measurements, and specific
local treatment effects, including bruising, swelling, pain,
lymphadenopathy, and pruritus. Assessment of the severity
of local treatment effects was made using a 6-point scale
from none (0) to extensive (5). Blood samples for the
determination of plasma anti-AUX-I and anti-AUX-II
antibody levels were collected (days 1, 30, 60). Blood
samples for pharmacokinetic evaluation were taken
15 minutes pre-dose on day 31 and at the following time
points following the multiple dose administration: 5, 10,
20, and 30 minutes and 1, 2, 4, 8, 12, and 24 hours(immediately following the finger extension procedure);
also, day 37 and 60.Statistical analyses
The safety population included all enrolled subjects. All
subjects were also included in the pharmacokinetic
population that received multiple injections of CCH in
treatment period 2. Efficacy, safety, and pharmacokinetic
variables are summarized with descriptive statistics.Results
Patient characteristics
Among the 12 subjects (11 males, 1 female), the mean age
was 64± 5.5 years and the mean age at symptom onset
was 50.5 ± 11.1 years. Six patients had a family history of
DC and 5 had previously undergone surgical correction
(2 fasciotomy, 3 fasciectomy), but the other 7 patients had
not received any treatment for DC. Of the patients who
had previously undergone surgical correction, only one
was injected with CCH in the same joint that had prior
surgical correction, and one other patient had surgery
(MP joint) and a CCH injection (PIP joint) in the same
finger but in two other joints. Additional baseline patient
information can be found in Table 1. Over the course of
the study, 22 MP joints and 14 PIP joints were treated
(Table 2). In treatment period 1, 5 MP joints and 7 PIP
joints were treated. In treatment period 2, 17 MP joints
and 7 PIP joints were treated. Most patients (n= 8) had
joints treated on different hands for treatment period 1
and 2, while 4 patients had joints treated on the same hand
but on different fingers. In treatment period 2, 5 subjects
had an MP and a PIP joint treated on the same finger, 2
subjects had an MP and a PIP joint treated on different
Table 1 Baseline patient characteristics (n = 12)
Characteristic Total
Mean age, years (SD) 63.7 (5.5)
Male, n (%) 11 (91.7)
Ethnicity, n (%)a
White, non-Hispanic 12 (100.0)
Weight (kg)
Mean (SD) 87.7 (8.4)
Range 74.0, 100.0
Height (cm)
Mean (SD) 177.2 (4.9)
Range 170.0, 188.0
Family history of Dupuytren’s contracture, n (%) 6 (50.0)
Age at symptom onset, years
Mean (SD) 50.5 (11.1)
Range 23.0, 65.0




Time since last hand surgery, years (n = 5)
Mean (SD) 5.6 (4.9)
Range 0.3, 10.0
aRace or ethnic group was self-reported.
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different fingers.
Efficacy
Results for efficacy endpoints collected following treat-
ment periods 1 and 2 are presented in Table 3. ForTable 2 Baseline joint characteristics for treatment periods 1
Characteristic Joints in Perio
MP joints, n (%) 5 (41.7)
Low baseline severity (≤50°) 5 (41.7)
High baseline severity (>50°) 0 (0.0)
Little finger 1 (8.3)
Ring finger 2 (16.7)
Middle finger 2 (16.7)
Index finger 0 (0.0)
PIP joints, n (%) 7 (58.3)
Low baseline severity (≤40°) 3 (25.0)
High baseline severity (>40°) 4 (33.3)
Little finger 1 (8.3)
Ring finger 3 (25.0)
Middle finger 0 (0.0)
Index finger 3 (25.0)
MP=metacarpophalangeal; PIP = proximal interphalangeal.treatment period 1, the mean reduction in contracture was
29.0± 20.7 degrees in the MP joints and 30.7 ± 21.1
degrees in the PIP joints (Figure 2A). This corresponded
to a percent change from baseline of 76.7% for the MP
joints and 65.3% for the PIP joints. The mean change in
range of motion increased by 29.0 ± 21.0 degrees in the
MP joints, and 32.1± 24.3 degrees in the PIP joints for
treatment period 1 (Figure 2B).
Following multiple injections in different joints given
in treatment period 2, the mean reduction in contracture
from baseline was 30.3 ± 10.9 degrees in the MP joints,
and 22.1 ± 4.9 degrees in the PIP joints (Figure 2A). This
corresponded to a percent change from baseline of
83.1% for the MP joints and 74.3% for the PIP joints.
The mean change in range of motion increased by
30.0 ± 10.8 degrees in the MP joints, and 17.1 ± 2.7
degrees in the PIP joints (Figure 2B).
Following a single injection in treatment period 1, 9
patients were “very satisfied” and 3 patients were “quite
satisfied” with their treatment. All 12 patients were “very
satisfied” with their treatment following the multiple
injections given concurrently in treatment period 2.
Pharmacokinetics
All pharmacokinetic samples were below the level of
quantification for both AUX-I and AUX-II, indicating no
detectable systemic exposure (limit of quantitation for
AUX-I = 5 ng/mL; AUX-II = 25 ng/mL).
Safety
The most common treatment-related AEs that occurred
during the study (single- and multiple-dose injection
periods) were all local events and included some degree of
edema peripheral [swelling in the treated extremity]and 2















Table 3 Treatment outcomes
Study endpoints Period 1 (Day 30) Period 2 (Day 60)
MP joints
Mean± SD change in contracture from baseline (degrees) 29.0 ± 20.7 30.3 ± 10.9
Mean± SD percent change in contracture from baseline 76.7 ± 52.2 83.1 ± 25.6
Mean± SD change in range of motion from baseline (degrees) 29.0 ± 21.0 30.0 ± 10.8
PIP joints
Mean± SD change in contracture from baseline (degrees) 30.7 ± 21.1 22.1 ± 4.9
Mean± SD percent change in contracture from baseline 65.3 ± 32.5 74.3 ± 27.7
Mean± SD change in range of motion from baseline (degrees) 32.1 ± 24.3 17.1 ± 2.7
MP=metacarpophalangeal; PIP = proximal interphalangeal.
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extremity (100%), lymphadenopathy (83.3%), and pruritus
(83.3%). Three adverse events, including edema peripheral,
contusion, and pain in the treated extremity, were
experienced by the majority of subjects (>80%) in both
treatment periods. When comparing treatment-related
AEs between treatment periods 1 and 2, a higher incidence
of pruritus was observed in treatment period 2 (Table 4).
One occurrence of paresthesia was noted in treatment
period 1 but was not observed in treatment period 2. Two
occurrences of blood blisters and one occurrence of skin
discoloration were observed in treatment period 2 but not
in period 1. Most of the treatment-related AEs were
observed beginning on the day of injection and only a few
were observed beginning beyond day 7 after the injection;
all resolved by the end of study (with the exception of 1
ongoing incidence of contusion [bruising]), and the mean
duration was 2 to 3 weeks for most AEs within both
periods. No systemic complications were observed.
The 5 most common local treatment-related effects were
graded according to a 6-point investigator-graded severity
scale (Table 5). In general, the differences in severity were
not clinically meaningful between treatment periods, and
no major differences were observed between treatment
periods by 30 days post-injection. Following treatment
period 2, all local events resolved by 60 days following
injection (eg, had a severity evaluation equal to “none”).
The only exception was the above-mentioned ongoing
contusion occurring after treatment period 2 that had a
severity evaluation equal to “negligible” at day 90.
Discussion
Surgical correction of affected joints is often used to
correct multiple contractures on the same hand during the
same procedure. However, surgery involving 3 or more
fingers, which most likely involves a more extensive
operation, has been shown to be significantly associated
with increased complications [15]. Typically, complica-
tions associated with surgery may include digital nerve or
artery injuries, wound-healing complications, dysesthesia/paresthesia, infection, and hematoma [10]. Needle
aponeurotomy is another treatment option for patients
with DC that is less invasive than open surgery and has
been shown to provide beneficial short-term results [16,17].
However, recurrence rates with needle aponeurotomy are
higher than those observed with fasciectomy, and many of
the same complications associated with fasciectomy have
been observed with this technique [16-18].
CCH is currently approved in both the US and EU for
adults with DC for treatment of a single palpable cord
during any 30-day treatment period, and has become an
acceptable alternative to surgical correction of DC. The
results from this exploratory study suggest comparable
improvement in contracture and range of motion per in-
jection of CCH when given as a single injection or when
multiple injections are administered concurrently, al-
though this study was not powered for statistical signifi-
cance. For the MP joints, mean change in contracture
was 29.0 ± 20.7 degrees following single injection or
30.3 ± 10.9 degrees following a single injection in the
multiple injection phase. Similar results were observed in
the change in range of motion with increases of
29.0 ± 21.0 and 30.0 ± 10.8 degrees in MP joints for single
and multiple phase injections, respectively. Comparable
but slightly less improved results were observed for PIP
joints following the single or multiple injection phase,
with mean change in contracture of 30.7 ± 21.1 vs
22.1 ± 4.9 degrees and change in range of motion of
32.1 ± 24.3 vs 17.1 ± 2.7 degrees, respectively.
In previously published studies that evaluated CCH
treatment of a single cord treated sequentially, the mean
reduction in contractures observed for MP joints (40.8
and 42.0 degrees) and PIP joints (32.7 and 32.2 degrees)
were comparable to mean reduction in contractures
observed following the single and multiple injection
phase in this study [13,14,19]. Comparable results were
observed for changes in range of motion in MP joints for
the single (29.0 ± 21.0 degrees) and multiple injection
phase (30.0 ± 10.8 degrees) and PIP joints following the
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Figure 2 A. Fixed flexion contracture at baseline and day 30 following a single injection (Period 1) or multiple injections in different
joints (Period 2). B. Range of motion at baseline and day 30 following a single injection (Period 1) or multiple injections in different joints
(Period 2). MP =metacarpophalangeal; PIP = proximal interphalangeal.
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joints and 29.0 and 32.0 degrees for PIP joints reported
in previously published studies [13,14]. Following the
multiple injection phase in which a PIP was one of
the joints injected, data values for mean change incontracture and change in range of motion were slightly
lower in this study compared to those reported
previously [13,14]. Some of these differences may be due
in part to the fact that the PIP joints did have a higher
baseline range of motion. Additional factors that may
Table 4 Treatment-related adverse events occurring in all subjects
Adverse event Period 1 (n = 12) Period 2 (n = 12)
Patients with ≥1 treatment-related adverse event, n (%) 12 (100) 12 (100)
Blood and lymphatic system disorders
Lymphadenopathy 6 (50) 7 (58.3)
General disorders and administration site conditions
Injection site discomfort 0 (0.0) 1 (8.3)
Injection site pain 3 (25.0) 5 (41.7)
Edema peripheral 12 (100) 12 (100)
Injury, poisoning and procedural complications
Contusion 12 (100) 12 (100)
Skin laceration 2 (16.7) 2 (16.7)
Musculoskeletal and connective tissue disorders
Pain in extremity 11 (91.7) 11 (91.7)
Nervous system disorders
Paresthesia 1 (8.3) 0 (0.0)
Skin and subcutaneous tissue disorders
Blood blister 0 (0.0) 2 (16.7)
Pruritus 5 (41.7) 10 (83.3)
Skin discoloration 0 (0.0) 1 (8.3)
Coleman et al. BMC Musculoskeletal Disorders 2012, 13:61 Page 7 of 8
http://www.biomedcentral.com/1471-2474/13/61account for these differences may include the small
number of subjects in this study and the variability in
treatment response often observed among individuals.
In this study, all blood samples were below quantifiable
levels for both AUX-I and AUX-II for both treatment
periods, consistent with results from an unpublished
single-dose pharmacokinetic study [19]. The results from
this study suggest that single and multiple concurrent
injections are similarly well tolerated. As expected, a
slightly greater severity of treatment-related AEs wasTable 5 Patients with “evident” and “considerable” local effec
Number of Patients (%
Local Treatment Effect Maximum Severitya PERIOD 1 (1 CCH inje
Day 2 Day 7
Bruising Evident 9 (75) 2 (17)
Considerable 1 (8) 0
Swelling Evident 2 (17) 1 (8)
Considerable 5 (42) 0
Pain Evident 5 (42) 0
Considerable 0 0
Lymphadenopathy Evident 3 (25) 0
Considerable 0 0
Pruritus Evident 3 (25) 0
Considerable 0 0
CCH= collagenase clostridium histolyticum.observed during treatment period 2, however, these AEs
resolved by day 30 after each injection. These local events
were directly solicited from investigators in an open label
setting, which may impact the reporting rate. No serious
treatment-related AEs were observed in this study
following both single and multiple injections. Reported
AEs were as expected following single and multiple
injections and compared to previously reported data.
Common AEs reported in this study and in previously
published studies were local reactions to CCH injection,ts following 1 or 2 injections for Dupuytren’s contracture
)
ction) (n = 12) PERIOD 2 (2 CCH injections) (n = 12)
Day 30 Day 2 Day 7 Day 30
0 6 (50) 3 (25) 0
0 3 (25) 1 (8) 0
0 6 (50) 3 (25) 0
0 2 (17) 0 0
0 3 (25) 0 0
0 2 (17) 0 0
0 1 (8) 0 0
0 1 (8) 0 0
0 0 0 0
0 2 (17) 0 0
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injection site pain, injection site hemorrhage, and
lymphadenopathy [13,14]. No reports of nerve or arterial
injury were observed following CCH injection in this or
the previously published studies [13,14]. Overall, the
safety results from this study are consistent with
previously published data and indicate that increasing
the number of injections given concurrently does not
meaningfully increase the rate or severity of observed AEs.
Conclusions
The results from this study suggest that two cords can be
treated concurrently with CCH with comparable efficacy
and safety as when a single cord is treated. The ability to
give multiple injections, without the need to wait 30 days
between treatments, would allow for a more rapid and
effective treatment of multiple affected joints in a fashion
similar to the surgical paradigm, and constitute a
significant advantage for both patient and physician.
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